Cigna Corporation Q1 2026 Earnings Recap

Shares of Cigna Group declined 3.2% post-earnings, as investor disappointment centered on the company's cautious full-year 2026 outlook despite management highlighting raised adjusted EPS guidance. The market response suggests concerns about decelerating growth, possibly tied to margin pressures or uncertainty in addressing rising healthcare costs.

Key Takeaways

• Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79.
• The company slightly raised its full-year 2026 adjusted EPS outlook to at least $30.35.
• Management emphasized efforts to address affordability and streamline healthcare access, including a 15% reduction in prior authorizations.
• A new rebate-free pharmacy service model (“Signature”) was introduced, targeting price transparency and reduced brand drug costs.
• The CEO transition to Brian Evanko is on track for July 1, with continued focus on cost control and innovation amid ongoing industry pressures.